Key result
A VE/VCO2 slope > 34 was associated with a higher risk of heart failure hospitalization or cardiovascular death compared to a slope ≤ 34.
Why the study?
Heart failure with preserved ejection fraction represents half of heart failure patients, but whether CPET parameters correlate with prognosis in these patients required investigation.
Does a VE/VCO2 slope > 34 on cardiopulmonary exercise testing predict heart failure hospitalizations and cardiovascular death in patients with newly diagnosed heart failure with preserved ejection fraction?
Cohort (n=99)
No
Does a VE/VCO2 slope > 34 on cardiopulmonary exercise testing predict heart failure hospitalizations and cardiovascular death in patients with newly diagnosed heart failure with preserved ejection fraction?
Answers are grounded in this paper and cite their sources.
A VE/VCO2 slope > 34 during cardiopulmonary exercise testing is a significant predictor of heart failure hospitalization and cardiovascular death in patients with newly diagnosed HFpEF.
Aims Patients with heart failure with preserved ejection fraction represent half of the heart failure patients nowadays, an at least steady trend due to the aging of the population. We investigated whether the parameters obtained from cardiopulmonary exercise testing (CPET) correlated with the prognosis of these patients. This prospective observational cohort study assesses the relationship between the CPET parameters peakVO2 and VE/VCO2 slope and the number of heart failure hospitalizations or cardiovascular death of these patients. Methods and results From August 2016 until May 2019, 99 patients from our outpatient unit with newly diagnosed heart failure with preserved ejection fraction underwent CPET. Median follow-up was 30 months [interquartile range, 24–38.5]. We selected peakVO2 < 14 mL/min/kg and a VE/VCO2 slope > 34 as threshold values for our primary clinically relevant endpoint, a composite of hospitalization for heart failure or cardiovascular death. Mean age was 75.07 ± 7.31 years, 49% were women, 75% were at NYHA class II and median NTproBNP was 511 pg/mL. Mean peakVO2 was 15.09 ± 4.75, and mean VE/VCO2 was 36.05 ± 6.60. During follow-up, there were 207 all-cause hospitalizations, 126 cardiovascular hospitalizations, 58 heart failure hospitalizations and 4 deaths. Over a median follow-up of 30 months, the primary clinically relevant endpoint occurred in 5 of 40 patients (12.5%) with a VE/VCO2 slope ≤ 34 and in 19 of 59 patients (32.2%) with a VE/VCO2 slope > 34 [hazard ratio, 2.69; 95% confidence interval (CI), 1.00–7.21; P = 0.04]. On multivariate analysis, VE/VCO2 slope was independently associated with heart failure hospitalization or cardiovascular death as a terminal event. Conclusions In patients with heart failure with preserved ejection fraction, a VE/VCO2 slope > 34 predicts heart failure hospitalizations and cardiovascular death.
No takes yet. Share an insight, caveat, or question.
Conceicao et al. (2025) conducted a cohort in Heart failure with preserved ejection fraction (n=99). VE/VCO2 slope > 34 vs. VE/VCO2 slope ≤ 34 was evaluated on Composite of hospitalization for heart failure or cardiovascular death (HR 2.69, 95% CI 1.00-7.21, p=0.04). A VE/VCO2 slope > 34 was associated with a higher risk of heart failure hospitalization or cardiovascular death compared to a slope ≤ 34.
Synapse has enriched 10 related papers. Consider them for comparative context: